Boehringer Ingelheim entered into a licensing agreement with Sitryx Therapeutics worth more than $500 million in total.[1][2] The deal includes exclusive global rights to a preclinical program of oral small molecules that target immunometabolic mechanisms in inflammatory and autoimmune diseases.[1][3] Sitryx may receive upfront payments, development, regulatory and commercialization milestone payments, as well as tiered sales royalties.[1][2] 2025 was a record year for Boehringer in the number of licensing agreements, with most of them focused on oncology and immunology.[1] In addition, Boehringer received expanded FDA approval for Hernexeos (zongertinib) for the treatment of chemotherapy-resistant NSCLC, following a previous approval in August 2025.[1] This Sitryx program is considered potentially disease-modifying through immune cell modulation.[1][6]